BioCentury
ARTICLE | Company News

Medarex and Novo Nordisk antibody deal

January 9, 2001 8:00 AM UTC

MEDX will use its UltiMAb human antibody and T-12 preclinical development systems to develop antibodies against disease targets identified by NVO. Under the agreement, NVO will develop and market resu...